Who makes BBP-418 (ribitol)?

BBP-418 (ribitol) is developed by ML Bio Solutions, Inc..

What development phase is BBP-418 (ribitol) in?

BBP-418 (ribitol) is in Phase 3.

Last reviewed 2026-04-22 · How we verify

BBP-418 (ribitol)

ML Bio Solutions, Inc. · Phase 3 active Small molecule

BBP-418 is a ribitol-based compound that modulates immune or metabolic pathways, though its precise mechanism remains proprietary.

At a glance

Generic name	BBP-418 (ribitol)
Sponsor	ML Bio Solutions, Inc.
Modality	Small molecule
Phase	Phase 3

Mechanism of action

Ribitol is a five-carbon sugar alcohol that may serve as a substrate or cofactor in cellular metabolism or immune signaling. As a phase 3 candidate from ML Bio Solutions, BBP-418 likely targets a specific disease pathway, but detailed mechanistic information is not publicly available in standard pharmaceutical databases.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BBP-418 (ribitol) CI brief — competitive landscape report
BBP-418 (ribitol) updates RSS · CI watch RSS
ML Bio Solutions, Inc. portfolio CI